Mind Medicine (MindMed) Inc
MNMD8.765USD
+0.325+3.85%
交易中 （美東）報價延遲15分鐘
664.42M總市值
虧損本益比TTM
關於 Mind Medicine (MindMed) Inc 公司
Mind Medicine (MindMed) Inc. 是一家臨牀階段的生物製藥公司，致力於開發治療腦部健康障礙的產品。該公司正在開發一系列具有和不具有急性感知效應的候選產品，以神經遞質通路爲目標。這具體包括源自迷幻藥和共情劑類藥物的經過藥物優化的候選產品，包括該公司的候選產品 MM-120 和 MM-402。MM120 是一種專有的、經過藥物優化的酒石酸麥角酸單抗，該公司正在開發這種藥物用於治療廣泛性焦慮症 (GAD)。MM-120 還正在研究一種亞感知重複給藥方案，用於治療注意力缺陷多動障礙 (ADHD)。 MM-402，也稱爲 R(-)-MDMA，是該公司的 3,4-亞甲基二氧基甲基苯丙胺 (MDMA) 的 R 對映體形式，該公司正在開發該形式用於治療自閉症譜系障礙 (ASD)。
公司簡介
公司代碼MNMD
公司名稱Mind Medicine (MindMed) Inc
上市日期May 04, 2015
CEOMr. Robert (Rob) Barrow
員工數量74
證券類型Ordinary Share
年結日May 04
公司地址One World Trade Center
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10007
電話12122206633
網址
公司代碼MNMD
上市日期May 04, 2015
CEOMr. Robert (Rob) Barrow
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
21.93%
Hedge Fund
17.33%
Investment Advisor
13.50%
Research Firm
1.70%
Individual Investor
1.09%
Bank and Trust
0.28%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Other
43.76%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
378
42.50M
56.25%
-6.01M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
2023Q1
386
7.15M
19.19%
-755.92K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
5.20M
6.88%
-370.12K
-6.64%
Mar 31, 2025
Commodore Capital LP
4.53M
5.99%
+216.57K
+5.03%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.75%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
3.35M
4.44%
-24.80K
-0.73%
Mar 31, 2025
Octagon Capital Advisors LP
3.02M
3.99%
--
--
Mar 31, 2025
Marshall Wace LLP
2.59M
3.43%
+91.77K
+3.67%
Mar 31, 2025
Deep Track Capital LP
2.50M
3.31%
-316.59K
-11.24%
Mar 31, 2025
State Street Global Advisors (US)
1.84M
2.44%
+60.72K
+3.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.75M
2.32%
-144.28K
-7.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.67M
2.21%
-56.30K
-3.27%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
AdvisorShares Psychedelics ETF
8.73%
SPDR S&P Pharmaceuticals ETF
0.85%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.6%
iShares U.S. Pharmaceuticals ETF
0.22%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Nuveen ESG Small-Cap ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
查看更多
AdvisorShares Psychedelics ETF
佔比8.73%
SPDR S&P Pharmaceuticals ETF
佔比0.85%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.6%
iShares U.S. Pharmaceuticals ETF
佔比0.22%
iShares Micro-Cap ETF
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
Nuveen ESG Small-Cap ETF
佔比0.04%
iShares Russell 2000 Value ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
公告日期
類型
比率
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
